Welcome to our dedicated page for InspireMD SEC filings (Ticker: NSPR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on InspireMD's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into InspireMD's regulatory disclosures and financial reporting.
InspireMD, Inc. director receives restricted stock grant. Director Gary S. Roubin reported an award of 88,053 shares of InspireMD common stock on January 14, 2026. The shares were acquired at a stated price of $0 per share as a stock award, increasing his beneficial ownership to 744,478 common shares held directly. The 88,053 shares are restricted stock that will vest on January 14, 2027, provided he continues to serve through that one-year grant anniversary date.
InspireMD, Inc. reported an equity grant to its Chief Financial Officer. A Form 4 shows CFO Michael Lawless received an award of 226,695 shares of common stock on January 14, 2026 at a price of $0 per share, increasing his directly held stake to 691,695 shares.
The new shares are restricted stock that vest in three equal annual installments, with one-third vesting on each of January 14, 2027, January 14, 2028, and January 14, 2029, as long as he continues in service with the company.
InspireMD, Inc. reported that Chief Commercial Officer Shane Gleason received an award of 453,390 shares of common stock on January 14, 2026 at a price of $0 per share.
These shares are restricted stock that vest in three equal annual installments on January 14, 2027, January 14, 2028 and January 14, 2029, conditioned on his continued service. After this grant, he directly beneficially owns 1,200,371 shares of InspireMD common stock.
InspireMD, Inc. director Danny L. Dearen reported a stock award of 44,030 shares of common stock on January 14, 2026. The Form 4 shows the shares were acquired at a price of $0 per share as a grant of restricted stock.
According to the footnote, these 44,030 shares are restricted stock that will vest on January 14, 2027, the one-year grant anniversary date, subject to his continued service. Following this grant, Dearen beneficially owns 102,047 shares of InspireMD common stock in direct ownership.
InspireMD, Inc. director Raymond W. Cohen reported receiving 44,030 shares of common stock on January 14, 2026 as an award of restricted stock. The shares were granted at a reported price of $0 per share, indicating an equity compensation grant rather than an open‑market purchase.
According to the filing, these restricted shares are scheduled to vest on January 14, 2027, subject to his continued service. After this grant, Cohen beneficially owned 92,417 shares of InspireMD common stock in direct ownership.
InspireMD, Inc. director Michael Berman reported an equity grant of common stock. On January 14, 2026, he received 88,053 shares of restricted common stock at a price of $0 per share, increasing his directly held beneficial ownership to 352,586 common shares.
The filing explains that these 88,053 shares are restricted stock that will vest on January 14, 2027, as long as he continues in service through that date. It also lists an additional 244,994 common shares as indirectly held through the Michael Berman Revocable Trust, with no transaction in those trust-held securities; they are included for informational reporting only.
InspireMD, Inc. director Paul Stuka reported an insider transaction involving 5,073 shares of the company's common stock on 12/09/2025 at a weighted average price of $1.81, with trades executed between $1.80 and $1.81 per share.
After this activity, he reports beneficial ownership of 391,628 shares held directly. A further 444,195 shares are held by Osiris Investment Partners, L.P., where he serves in a managing capacity; he may be deemed to beneficially own these but expressly disclaims beneficial ownership except to the extent of his pecuniary interest, and states that no transaction occurred in those indirect holdings.
InspireMD, Inc. filed a Form S-8 to register an additional 4,723,370 shares of common stock, par value $0.0001 per share, for issuance under its 2021 Equity Compensation Plan. This expands the pool of shares available for grants such as stock options and restricted stock to employees and other eligible participants in the plan. The filing incorporates by reference the company’s latest Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, certain Current Reports on Form 8-K, and other key governance documents, and includes legal opinions and auditor consents supporting the registration.
InspireMD (NSPR) director insider buy: A reporting person serving as a director purchased 13,431 shares of common stock on 11/12/2025 at $1.62 per share.
After the purchase, the filing shows 373,715 shares beneficially owned directly. It also lists 444,195 shares held indirectly through Osiris Investment Partners, L.P.; the filing states the reporting person may be deemed to beneficially own those only to the extent of any pecuniary interest and includes them for informational purposes.
The signature indicates the report was filed by an attorney-in-fact for the reporting person.
InspireMD (NSPR) filed its Q3 2025 10‑Q, highlighting the first U.S. sales of CGuard Prime after FDA PMA approval in June and a July commercial launch. Revenue rose to $2.523 million from $1.810 million a year ago as U.S. direct sales began and international distributor sales grew. Gross profit improved to $864,000 from $414,000, with gross margin up to 34.2%.
Operating investments to build U.S. commercialization drove higher expenses: R&D $3.635 million, S&M $4.392 million, and G&A $5.888 million. Net loss widened to $12.708 million (loss per share $0.17) versus $7.890 million last year.
Liquidity strengthened from financings and warrant exercises. Cash and cash equivalents were $63.403 million at September 30, 2025. The company closed a private placement with roughly $40.1 million in gross proceeds and received $16.9 million net from Series I warrant exercises. Despite this, management disclosed substantial doubt about the ability to continue as a going concern given expected operating losses until commercial profitability. Shares outstanding were 41,919,141 as of September 30, 2025; 42,370,995 as of November 10, 2025.